Integrating Mechanistic Insights from Diverse Models to Prevent CMV Reactivation following Transplantation
整合不同模型的机制见解以防止移植后 CMV 重新激活
基本信息
- 批准号:9303245
- 负责人:
- 金额:$ 231.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-01 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnimal ModelAntigensAntiviral AgentsBone MarrowCell Culture TechniquesCell Differentiation processCell LineageCell SeparationChromatinChronicClinicalClinical ResearchCytomegalovirusCytomegalovirus InfectionsDNA-Directed DNA PolymeraseDevelopmentEffectivenessEnvironmentEnzymesEpigenetic ProcessFosteringGene ExpressionGoalsGraft RejectionHematopoietic stem cellsHistonesHistopathologyHumanImmediate-Early GenesImmuneImmune responseImmunosuppressionImmunosuppressive AgentsIn VitroInfectionInflammation MediatorsInflammatoryInflammatory ResponseKidney TransplantationLeadLifeMediatingModelingModificationMolecularMolecular VirologyMurid herpesvirus 1MusMyelogenousMyeloid Progenitor CellsOperative Surgical ProceduresOrgan TransplantationPharmaceutical PreparationsProtocols documentationResearchServicesSignal PathwaySignal TransductionSiteTestingTherapeuticToxic effectTransplant RecipientsTransplantationTransplantation ToleranceViral GenesViral GenomeVirusVirus Latencyclinically relevantdesigngene repressiongenome-widehistone modificationimproved outcomein vitro Modelin vivoinsightlytic replicationmouse modelnovel strategiespreventprogramsprophylacticpublic health relevancereactivation from latencyresistant strainsynergismtranscription factorviral DNA
项目摘要
DESCRIPTION (provided by applicant): Overall Reactivation of latent Cytomegalovirus (CMV) remains an important clinical problem following transplantation, despite the prophylactic use of efficacious antiviral agents. Because these target the viral DNA polymerase, they are only active after the virus has reactivated from latency. Their effectiveness is also limited by toxicities and
by the emergence of resistant strains. Donor- specific allo-immune tolerance, whereby a transplant recipient is hypo-responsive to donor antigens but continues to have intact immune-responsiveness to other foreign antigens has been the `Holy Grail' of transplantation since the early 1950's. Recently, several experimental protocols have achieved this goal, and the `era of tolerance' seems near. Prior studies have demonstrated that murine CMV (MCMV) reactivation requires the combination of an allo-inflammatory response and immunosuppressive drugs (ISD), while a donor-specific tolerant model would abrogate the inflammatory response, and avoid the need for ISD. Also recently, two central themes have emerged from a combination of studies of animal models of MCMV reactivation and ex vivo/in vitro models of HCMV reactivation: expression of viral genes involved in lytic replication is repressed by epigenetic factors that induce heterochromatinization of viral genomes; and signaling pathways activated by an inflammatory immune response induce reactivation of the virus through epigenetic reprogramming of viral DNA, such that the immediate early genes are released from transcriptional repression, leading to lytic replication. These themes form the basis for studies proposed in 3 separate but inter-related projects studying: 1) Mechanisms of reactivation of latent MCMV following kidney transplantation in a clinically relevant model; 2) Mechanisms of latency and reactivation of HCMV in myeloid lineage cells; and 3) MCMV infection, latency and reactivation in transplantation tolerance. Three Cores will support services needed for the successful completion of studies within these Projects: A) Microvascular surgery and histopathology; B) Precision cell isolation and analysis; and C) Administrative services. The unifying and central hypothesis of the Program Project is that reactivation of latent CMV is induced by inflammatory mediators, which activate signaling pathways, leading to epigenetic reprogramming of viral genomes, resulting in induction of immediate early (IE) gene expression, and ultimately, to reactivation of infectious virus. We believe that blockade of these signaling pathways, either by interfering with specific signaling pathways, blocking epigenetic modifications, or by donor- specific tolerance, prevent reactivation of CMV. We anticipate that integrating mechanistic insights derived from the three projects in this highly collaborative effor will be decisive in moving the field forward and in fostering the development of novel strategies to prevent, rather than treat CMV reactivation.
描述(由申请方提供):尽管预防性使用了有效的抗病毒药物,但移植后潜伏巨细胞病毒(CMV)的总体再活化仍然是一个重要的临床问题。因为这些靶向病毒DNA聚合酶,它们只有在病毒从潜伏期重新激活后才有活性。它们的有效性也受到毒性的限制,
抵抗性菌株的出现。供体特异性同种异体免疫耐受,即移植受体对供体抗原低应答,但对其它外源抗原继续具有完整的免疫应答,自20世纪50年代初以来一直是移植的“圣杯”。最近,几项实验方案已经实现了这一目标,“容忍时代”似乎即将到来。先前的研究已经证明,鼠CMV(MCMV)再活化需要同种异体炎症反应和免疫抑制药物(ISD)的组合,而供体特异性耐受模型将消除炎症反应,并避免对ISD的需要。同样在最近,从MCMV再活化的动物模型和HCMV再活化的离体/体外模型的组合研究中出现了两个中心主题:参与裂解复制的病毒基因的表达被诱导病毒基因组异染色质化的表观遗传因子抑制;并且由炎性免疫应答激活的信号传导途径通过病毒DNA的表观遗传重编程诱导病毒的再活化,使得立即早期基因从转录抑制中释放,导致裂解性复制。这些主题形成了3个独立但相互关联的项目中提出的研究基础,这些项目研究:1)临床相关模型中肾移植后潜伏MCMV再激活的机制; 2)髓系细胞中HCMV潜伏和再激活的机制; 3)移植耐受中MCMV感染、潜伏和再激活。三个核心将支持成功完成这些项目研究所需的服务:A)微血管手术和组织病理学; B)精确细胞分离和分析;以及C)行政服务。该计划项目的统一和中心假设是,潜伏CMV的再激活是由炎症介质诱导的,炎症介质激活信号通路,导致病毒基因组的表观遗传重编程,导致诱导立即早期(IE)基因表达,并最终导致感染性病毒的再激活。我们认为,通过干扰特定信号传导途径、阻断表观遗传修饰或通过供体特异性耐受来阻断这些信号传导途径,可以防止CMV的再激活。我们预计,在这个高度合作的effor中整合来自三个项目的机制见解将决定性地推动该领域的发展,并促进新策略的发展,以预防而不是治疗CMV再激活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael M Abecassis其他文献
Michael M Abecassis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael M Abecassis', 18)}}的其他基金
Integrating Mechanistic Insights from Diverse Models to Prevent CMV Reactivation following Transplantation
整合不同模型的机制见解以防止移植后 CMV 重新激活
- 批准号:
8934950 - 财政年份:2015
- 资助金额:
$ 231.72万 - 项目类别:
Integrating Mechanistic Insights from Diverse Models to Prevent CMV Reactivation following Transplantation
整合不同模型的机制见解以防止移植后 CMV 重新激活
- 批准号:
9099718 - 财政年份:2015
- 资助金额:
$ 231.72万 - 项目类别:
Mechanisms of MCMV reactivation in immunodeficient transplant recipients
免疫缺陷移植受者中 MCMV 再激活的机制
- 批准号:
9295934 - 财政年份:2014
- 资助金额:
$ 231.72万 - 项目类别:
Role of innate immunity and injury in transplant-induced reactivation of MCMV
先天免疫和损伤在移植诱导的 MCMV 重新激活中的作用
- 批准号:
8227285 - 财政年份:2012
- 资助金额:
$ 231.72万 - 项目类别:
Role of innate immunity and injury in transplant-induced reactivation of MCMV
先天免疫和损伤在移植诱导的 MCMV 重新激活中的作用
- 批准号:
8435351 - 财政年份:2012
- 资助金额:
$ 231.72万 - 项目类别:
Biomarker Profiles for Prediction and Diagnosis of Post-Transplant Renal Injury
用于预测和诊断移植后肾损伤的生物标志物谱
- 批准号:
7804107 - 财政年份:2010
- 资助金额:
$ 231.72万 - 项目类别:
Role of Toll-like Receptors in Transplant-Induced Reactivation of Cytomegalovirus
Toll 样受体在移植诱导的巨细胞病毒再激活中的作用
- 批准号:
8086118 - 财政年份:2010
- 资助金额:
$ 231.72万 - 项目类别:
Living Donor Liver Transplant - Predictive Models for Long-Term Health Outcomes
活体肝移植 - 长期健康结果的预测模型
- 批准号:
8014622 - 财政年份:2010
- 资助金额:
$ 231.72万 - 项目类别:
Proteogenomics for Organ Transplantation: Prediction, Diagnosis, Intervention
器官移植的蛋白质基因组学:预测、诊断、干预
- 批准号:
8131698 - 财政年份:2009
- 资助金额:
$ 231.72万 - 项目类别:
Role of Toll-like Receptors in Transplant-Induced Reactivation of Cytomegalovirus
Toll 样受体在移植诱导的巨细胞病毒再激活中的作用
- 批准号:
7739139 - 财政年份:2009
- 资助金额:
$ 231.72万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 231.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists